 | • レポートコード：MRC2-11QY10876 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、152ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗原虫薬のグローバル市場について調査・分析したレポートです。種類別（アメーバ赤痢、抗マラリア薬、リーシュマニア症、シャーガス病）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗原虫薬の競争状況、市場シェア ・世界の抗原虫薬市場：種類別市場規模 2015年-2020年（アメーバ赤痢、抗マラリア薬、リーシュマニア症、シャーガス病） ・世界の抗原虫薬市場：種類別市場規模予測 2021年-2026年（アメーバ赤痢、抗マラリア薬、リーシュマニア症、シャーガス病） ・世界の抗原虫薬市場：用途別市場規模 2015年-2020年（病院、クリニック） ・世界の抗原虫薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック） ・北米の抗原虫薬市場分析：米国、カナダ ・ヨーロッパの抗原虫薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗原虫薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗原虫薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗原虫薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Sanofi、Akthelia Pharmaceuticals Ltd、GlaxoSmithKline Plc、Immuron Ltd、Microbiotix Inc、Protein Potential LLC、Dr. Reddy’s Laboratories、Mission Pharmacal、Aceto Corp.、Mylan Pharmaceuticals、Impax Laboratories、Pfizer、Lupin Pharmaceuticals、Glenmark Pharmaceuticals、Sun Pharmaceutical、Heritage Pharmaceuticals、Gilead Sciences、Johnson & Johnson、Bristol-Myers Squibb、Profounda、Knight Therapeutics、Albert David、Wanlong、Fangsheng、KPC Pharmaceuticals、Guilin Pharmaceuticals、Pude Pharmaceutica ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.
Antiprotozoals are used to treat protozoal infections, which include amebiasis, giardiasis, cryptosporidiosis, microsporidiosis, malaria, babesiosis, trypanosomiasis, Chagas disease, leishmaniasis, and toxoplasmosis.[5] Currently, many of the treatments for these infections are limited by their toxicity. Some antiprotozoal drugs include the antimalarials Aralen (chloroquine), Daraprim (pyrimethamine), Lariam (mefloquine) and Plaquenil (hydroxychloroquine); Flagyl (metronidazole) which is active against Entamoeba histolytica and Trichomonas vaginalis; and Mepron (atovaquone) for Pneumocystis carinii.
Market Analysis and Insights: Global Antiprotozoal Drugs Market
The global Antiprotozoal Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antiprotozoal Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antiprotozoal Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antiprotozoal Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antiprotozoal Drugs market.
Global Antiprotozoal Drugs Scope and Market Size
Antiprotozoal Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antiprotozoal Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
by Diseases
Amoebic Dysentery
Antimalarial Drug
Leishmaniasis & Chagas Disease
by Drugs
Metronidazole
Atovaquone
Benznidazole
Dehydroemetine
Eflornithine
Emetine
Fenbendazole
Iodoquinol
Melarsoprol
Others (like Meglumine antimonite, Nifurtimox, Pentamidine, etc.)
Market segment by Application, split into
Hospital
Clinic
Based on regional and country-level analysis, the Antiprotozoal Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Antiprotozoal Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Sanofi
Akthelia Pharmaceuticals Ltd
GlaxoSmithKline Plc
Immuron Ltd
Microbiotix Inc
Protein Potential LLC
Dr. Reddy’s Laboratories
Mission Pharmacal
Aceto Corp.
Mylan Pharmaceuticals
Impax Laboratories
Pfizer
Lupin Pharmaceuticals
Glenmark Pharmaceuticals
Sun Pharmaceutical
Heritage Pharmaceuticals
Gilead Sciences
Johnson & Johnson
Bristol-Myers Squibb
Profounda
Knight Therapeutics
Albert David
Wanlong
Fangsheng
KPC Pharmaceuticals
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antiprotozoal Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Amoebic Dysentery
1.2.3 Antimalarial Drug
1.2.4 Leishmaniasis & Chagas Disease
1.3 Market by Application
1.3.1 Global Antiprotozoal Drugs Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antiprotozoal Drugs Market Perspective (2015-2026)
2.2 Global Antiprotozoal Drugs Growth Trends by Regions
2.2.1 Antiprotozoal Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Antiprotozoal Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Antiprotozoal Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antiprotozoal Drugs Players by Market Size
3.1.1 Global Top Antiprotozoal Drugs Players by Revenue (2015-2020)
3.1.2 Global Antiprotozoal Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Antiprotozoal Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antiprotozoal Drugs Revenue
3.4 Global Antiprotozoal Drugs Market Concentration Ratio
3.4.1 Global Antiprotozoal Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antiprotozoal Drugs Revenue in 2019
3.5 Key Players Antiprotozoal Drugs Area Served
3.6 Key Players Antiprotozoal Drugs Product Solution and Service
3.7 Date of Enter into Antiprotozoal Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antiprotozoal Drugs Breakdown Data by Type (2015-2026)
4.1 Global Antiprotozoal Drugs Historic Market Size by Type (2015-2020)
4.2 Global Antiprotozoal Drugs Forecasted Market Size by Type (2021-2026)
5 Antiprotozoal Drugs Breakdown Data by Application (2015-2026)
5.1 Global Antiprotozoal Drugs Historic Market Size by Application (2015-2020)
5.2 Global Antiprotozoal Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Antiprotozoal Drugs Market Size (2015-2026)
6.2 North America Antiprotozoal Drugs Market Size by Type (2015-2020)
6.3 North America Antiprotozoal Drugs Market Size by Application (2015-2020)
6.4 North America Antiprotozoal Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Antiprotozoal Drugs Market Size (2015-2026)
7.2 Europe Antiprotozoal Drugs Market Size by Type (2015-2020)
7.3 Europe Antiprotozoal Drugs Market Size by Application (2015-2020)
7.4 Europe Antiprotozoal Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Antiprotozoal Drugs Market Size (2015-2026)
8.2 China Antiprotozoal Drugs Market Size by Type (2015-2020)
8.3 China Antiprotozoal Drugs Market Size by Application (2015-2020)
8.4 China Antiprotozoal Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Antiprotozoal Drugs Market Size (2015-2026)
9.2 Japan Antiprotozoal Drugs Market Size by Type (2015-2020)
9.3 Japan Antiprotozoal Drugs Market Size by Application (2015-2020)
9.4 Japan Antiprotozoal Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 India
10.1 India Antiprotozoal Drugs Market Size (2015-2026)
10.2 India Antiprotozoal Drugs Market Size by Type (2015-2020)
10.3 India Antiprotozoal Drugs Market Size by Application (2015-2020)
10.4 India Antiprotozoal Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Antiprotozoal Drugs Introduction
11.1.4 Sanofi Revenue in Antiprotozoal Drugs Business (2015-2020))
11.1.5 Sanofi Recent Development
11.2 Akthelia Pharmaceuticals Ltd
11.2.1 Akthelia Pharmaceuticals Ltd Company Details
11.2.2 Akthelia Pharmaceuticals Ltd Business Overview
11.2.3 Akthelia Pharmaceuticals Ltd Antiprotozoal Drugs Introduction
11.2.4 Akthelia Pharmaceuticals Ltd Revenue in Antiprotozoal Drugs Business (2015-2020)
11.2.5 Akthelia Pharmaceuticals Ltd Recent Development
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Company Details
11.3.2 GlaxoSmithKline Plc Business Overview
11.3.3 GlaxoSmithKline Plc Antiprotozoal Drugs Introduction
11.3.4 GlaxoSmithKline Plc Revenue in Antiprotozoal Drugs Business (2015-2020)
11.3.5 GlaxoSmithKline Plc Recent Development
11.4 Immuron Ltd
11.4.1 Immuron Ltd Company Details
11.4.2 Immuron Ltd Business Overview
11.4.3 Immuron Ltd Antiprotozoal Drugs Introduction
11.4.4 Immuron Ltd Revenue in Antiprotozoal Drugs Business (2015-2020)
11.4.5 Immuron Ltd Recent Development
11.5 Microbiotix Inc
11.5.1 Microbiotix Inc Company Details
11.5.2 Microbiotix Inc Business Overview
11.5.3 Microbiotix Inc Antiprotozoal Drugs Introduction
11.5.4 Microbiotix Inc Revenue in Antiprotozoal Drugs Business (2015-2020)
11.5.5 Microbiotix Inc Recent Development
11.6 Protein Potential LLC
11.6.1 Protein Potential LLC Company Details
11.6.2 Protein Potential LLC Business Overview
11.6.3 Protein Potential LLC Antiprotozoal Drugs Introduction
11.6.4 Protein Potential LLC Revenue in Antiprotozoal Drugs Business (2015-2020)
11.6.5 Protein Potential LLC Recent Development
11.7 Dr. Reddy’s Laboratories
11.7.1 Dr. Reddy’s Laboratories Company Details
11.7.2 Dr. Reddy’s Laboratories Business Overview
11.7.3 Dr. Reddy’s Laboratories Antiprotozoal Drugs Introduction
11.7.4 Dr. Reddy’s Laboratories Revenue in Antiprotozoal Drugs Business (2015-2020)
11.7.5 Dr. Reddy’s Laboratories Recent Development
11.8 Mission Pharmacal
11.8.1 Mission Pharmacal Company Details
11.8.2 Mission Pharmacal Business Overview
11.8.3 Mission Pharmacal Antiprotozoal Drugs Introduction
11.8.4 Mission Pharmacal Revenue in Antiprotozoal Drugs Business (2015-2020)
11.8.5 Mission Pharmacal Recent Development
11.9 Aceto Corp.
11.9.1 Aceto Corp. Company Details
11.9.2 Aceto Corp. Business Overview
11.9.3 Aceto Corp. Antiprotozoal Drugs Introduction
11.9.4 Aceto Corp. Revenue in Antiprotozoal Drugs Business (2015-2020)
11.9.5 Aceto Corp. Recent Development
11.10 Mylan Pharmaceuticals
11.10.1 Mylan Pharmaceuticals Company Details
11.10.2 Mylan Pharmaceuticals Business Overview
11.10.3 Mylan Pharmaceuticals Antiprotozoal Drugs Introduction
11.10.4 Mylan Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
11.10.5 Mylan Pharmaceuticals Recent Development
11.11 Impax Laboratories
10.11.1 Impax Laboratories Company Details
10.11.2 Impax Laboratories Business Overview
10.11.3 Impax Laboratories Antiprotozoal Drugs Introduction
10.11.4 Impax Laboratories Revenue in Antiprotozoal Drugs Business (2015-2020)
10.11.5 Impax Laboratories Recent Development
11.12 Pfizer
10.12.1 Pfizer Company Details
10.12.2 Pfizer Business Overview
10.12.3 Pfizer Antiprotozoal Drugs Introduction
10.12.4 Pfizer Revenue in Antiprotozoal Drugs Business (2015-2020)
10.12.5 Pfizer Recent Development
11.13 Lupin Pharmaceuticals
10.13.1 Lupin Pharmaceuticals Company Details
10.13.2 Lupin Pharmaceuticals Business Overview
10.13.3 Lupin Pharmaceuticals Antiprotozoal Drugs Introduction
10.13.4 Lupin Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
10.13.5 Lupin Pharmaceuticals Recent Development
11.14 Glenmark Pharmaceuticals
10.14.1 Glenmark Pharmaceuticals Company Details
10.14.2 Glenmark Pharmaceuticals Business Overview
10.14.3 Glenmark Pharmaceuticals Antiprotozoal Drugs Introduction
10.14.4 Glenmark Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
10.14.5 Glenmark Pharmaceuticals Recent Development
11.15 Sun Pharmaceutical
10.15.1 Sun Pharmaceutical Company Details
10.15.2 Sun Pharmaceutical Business Overview
10.15.3 Sun Pharmaceutical Antiprotozoal Drugs Introduction
10.15.4 Sun Pharmaceutical Revenue in Antiprotozoal Drugs Business (2015-2020)
10.15.5 Sun Pharmaceutical Recent Development
11.16 Heritage Pharmaceuticals
10.16.1 Heritage Pharmaceuticals Company Details
10.16.2 Heritage Pharmaceuticals Business Overview
10.16.3 Heritage Pharmaceuticals Antiprotozoal Drugs Introduction
10.16.4 Heritage Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
10.16.5 Heritage Pharmaceuticals Recent Development
11.17 Gilead Sciences
10.17.1 Gilead Sciences Company Details
10.17.2 Gilead Sciences Business Overview
10.17.3 Gilead Sciences Antiprotozoal Drugs Introduction
10.17.4 Gilead Sciences Revenue in Antiprotozoal Drugs Business (2015-2020)
10.17.5 Gilead Sciences Recent Development
11.18 Johnson & Johnson
10.18.1 Johnson & Johnson Company Details
10.18.2 Johnson & Johnson Business Overview
10.18.3 Johnson & Johnson Antiprotozoal Drugs Introduction
10.18.4 Johnson & Johnson Revenue in Antiprotozoal Drugs Business (2015-2020)
10.18.5 Johnson & Johnson Recent Development
11.19 Bristol-Myers Squibb
10.19.1 Bristol-Myers Squibb Company Details
10.19.2 Bristol-Myers Squibb Business Overview
10.19.3 Bristol-Myers Squibb Antiprotozoal Drugs Introduction
10.19.4 Bristol-Myers Squibb Revenue in Antiprotozoal Drugs Business (2015-2020)
10.19.5 Bristol-Myers Squibb Recent Development
11.20 Profounda
10.20.1 Profounda Company Details
10.20.2 Profounda Business Overview
10.20.3 Profounda Antiprotozoal Drugs Introduction
10.20.4 Profounda Revenue in Antiprotozoal Drugs Business (2015-2020)
10.20.5 Profounda Recent Development
11.21 Knight Therapeutics
10.21.1 Knight Therapeutics Company Details
10.21.2 Knight Therapeutics Business Overview
10.21.3 Knight Therapeutics Antiprotozoal Drugs Introduction
10.21.4 Knight Therapeutics Revenue in Antiprotozoal Drugs Business (2015-2020)
10.21.5 Knight Therapeutics Recent Development
11.22 Albert David
10.22.1 Albert David Company Details
10.22.2 Albert David Business Overview
10.22.3 Albert David Antiprotozoal Drugs Introduction
10.22.4 Albert David Revenue in Antiprotozoal Drugs Business (2015-2020)
10.22.5 Albert David Recent Development
11.23 Wanlong
10.23.1 Wanlong Company Details
10.23.2 Wanlong Business Overview
10.23.3 Wanlong Antiprotozoal Drugs Introduction
10.23.4 Wanlong Revenue in Antiprotozoal Drugs Business (2015-2020)
10.23.5 Wanlong Recent Development
11.24 Fangsheng
10.24.1 Fangsheng Company Details
10.24.2 Fangsheng Business Overview
10.24.3 Fangsheng Antiprotozoal Drugs Introduction
10.24.4 Fangsheng Revenue in Antiprotozoal Drugs Business (2015-2020)
10.24.5 Fangsheng Recent Development
11.25 KPC Pharmaceuticals
10.25.1 KPC Pharmaceuticals Company Details
10.25.2 KPC Pharmaceuticals Business Overview
10.25.3 KPC Pharmaceuticals Antiprotozoal Drugs Introduction
10.25.4 KPC Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
10.25.5 KPC Pharmaceuticals Recent Development
11.26 Guilin Pharmaceuticals
10.26.1 Guilin Pharmaceuticals Company Details
10.26.2 Guilin Pharmaceuticals Business Overview
10.26.3 Guilin Pharmaceuticals Antiprotozoal Drugs Introduction
10.26.4 Guilin Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
10.26.5 Guilin Pharmaceuticals Recent Development
11.27 Pude Pharmaceutica
10.27.1 Pude Pharmaceutica Company Details
10.27.2 Pude Pharmaceutica Business Overview
10.27.3 Pude Pharmaceutica Antiprotozoal Drugs Introduction
10.27.4 Pude Pharmaceutica Revenue in Antiprotozoal Drugs Business (2015-2020)
10.27.5 Pude Pharmaceutica Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Antiprotozoal Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Amoebic Dysentery
Table 4. Key Players of Antimalarial Drug
Table 5. Key Players of Leishmaniasis & Chagas Disease
Table 6. Global Antiprotozoal Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 7. Global Antiprotozoal Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 8. Global Antiprotozoal Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 9. Global Antiprotozoal Drugs Market Share by Regions (2015-2020)
Table 10. Global Antiprotozoal Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 11. Global Antiprotozoal Drugs Market Share by Regions (2021-2026)
Table 12. Antiprotozoal Drugs Market Market Trends
Table 13. Antiprotozoal Drugs Market Drivers
Table 14. Antiprotozoal Drugs Market Challenges
Table 15. Antiprotozoal Drugs Market Restraints
Table 16. Global Antiprotozoal Drugs Revenue by Players (2015-2020) (US$ Million)
Table 17. Global Antiprotozoal Drugs Market Share by Players (2015-2020)
Table 18. Global Top Antiprotozoal Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antiprotozoal Drugs as of 2019)
Table 19. Global Antiprotozoal Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Antiprotozoal Drugs Product Solution and Service
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antiprotozoal Drugs Market Size by Type (2015-2020) (US$ Million)
Table 24. Global Antiprotozoal Drugs Market Size Share by Type (2015-2020)
Table 25. Global Antiprotozoal Drugs Revenue Market Share by Type (2021-2026)
Table 26. Global Antiprotozoal Drugs Market Size Share by Application (2015-2020)
Table 27. Global Antiprotozoal Drugs Market Size by Application (2015-2020) (US$ Million)
Table 28. Global Antiprotozoal Drugs Market Size Share by Application (2021-2026)
Table 29. North America Antiprotozoal Drugs Market Size by Type (2015-2020) (US$ Million)
Table 30. North America Antiprotozoal Drugs Market Share by Type (2015-2020)
Table 31. North America Antiprotozoal Drugs Market Size by Application (2015-2020) (US$ Million)
Table 32. North America Antiprotozoal Drugs Market Share by Application (2015-2020)
Table 33. North America Antiprotozoal Drugs Market Size by Country (US$ Million) (2015-2020)
Table 34. North America Antiprotozoal Drugs Market Share by Country (2015-2020)
Table 35. Europe Antiprotozoal Drugs Market Size by Type (2015-2020) (US$ Million)
Table 36. Europe Antiprotozoal Drugs Market Share by Type (2015-2020)
Table 37. Europe Antiprotozoal Drugs Market Size by Application (2015-2020) (US$ Million)
Table 38. Europe Antiprotozoal Drugs Market Share by Application (2015-2020)
Table 39. Europe Antiprotozoal Drugs Market Size by Country (US$ Million) (2015-2020)
Table 40. Europe Antiprotozoal Drugs Market Share by Country (2015-2020)
Table 41. China Antiprotozoal Drugs Market Size by Type (2015-2020) (US$ Million)
Table 42. China Antiprotozoal Drugs Market Share by Type (2015-2020)
Table 43. China Antiprotozoal Drugs Market Size by Application (2015-2020) (US$ Million)
Table 44. China Antiprotozoal Drugs Market Share by Application (2015-2020)
Table 45. China Antiprotozoal Drugs Market Size by Region (US$ Million) (2015-2020)
Table 46. China Antiprotozoal Drugs Market Share by Region (2015-2020)
Table 47. Japan Antiprotozoal Drugs Market Size by Type (2015-2020) (US$ Million)
Table 48. Japan Antiprotozoal Drugs Market Share by Type (2015-2020)
Table 49. Japan Antiprotozoal Drugs Market Size by Application (2015-2020) (US$ Million)
Table 50. Japan Antiprotozoal Drugs Market Share by Application (2015-2020)
Table 51. Japan Antiprotozoal Drugs Market Size by Country (US$ Million) (2015-2020)
Table 52. Japan Antiprotozoal Drugs Market Share by Country (2015-2020)
Table 53. India Antiprotozoal Drugs Market Size by Type (2015-2020) (US$ Million)
Table 54. India Antiprotozoal Drugs Market Share by Type (2015-2020)
Table 55. India Antiprotozoal Drugs Market Size by Application (2015-2020) (US$ Million)
Table 56. India Antiprotozoal Drugs Market Share by Application (2015-2020)
Table 57. India Antiprotozoal Drugs Market Size by Country (US$ Million) (2015-2020)
Table 58. India Antiprotozoal Drugs Market Share by Country (2015-2020)
Table 59. Sanofi Company Details
Table 60. Sanofi Business Overview
Table 61. Sanofi Product
Table 62. Sanofi Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 63. Sanofi Recent Development
Table 64. Akthelia Pharmaceuticals Ltd Company Details
Table 65. Akthelia Pharmaceuticals Ltd Business Overview
Table 66. Akthelia Pharmaceuticals Ltd Product
Table 67. Akthelia Pharmaceuticals Ltd Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 68. Akthelia Pharmaceuticals Ltd Recent Development
Table 69. GlaxoSmithKline Plc Company Details
Table 70. GlaxoSmithKline Plc Business Overview
Table 71. GlaxoSmithKline Plc Product
Table 72. GlaxoSmithKline Plc Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 73. GlaxoSmithKline Plc Recent Development
Table 74. Immuron Ltd Company Details
Table 75. Immuron Ltd Business Overview
Table 76. Immuron Ltd Product
Table 77. Immuron Ltd Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 78. Immuron Ltd Recent Development
Table 79. Microbiotix Inc Company Details
Table 80. Microbiotix Inc Business Overview
Table 81. Microbiotix Inc Product
Table 82. Microbiotix Inc Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 83. Microbiotix Inc Recent Development
Table 84. Protein Potential LLC Company Details
Table 85. Protein Potential LLC Business Overview
Table 86. Protein Potential LLC Product
Table 87. Protein Potential LLC Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 88. Protein Potential LLC Recent Development
Table 89. Dr. Reddy’s Laboratories Company Details
Table 90. Dr. Reddy’s Laboratories Business Overview
Table 91. Dr. Reddy’s Laboratories Product
Table 92. Dr. Reddy’s Laboratories Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 93. Dr. Reddy’s Laboratories Recent Development
Table 94. Mission Pharmacal Business Overview
Table 95. Mission Pharmacal Product
Table 96. Mission Pharmacal Company Details
Table 97. Mission Pharmacal Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 98. Mission Pharmacal Recent Development
Table 99. Aceto Corp. Company Details
Table 100. Aceto Corp. Business Overview
Table 101. Aceto Corp. Product
Table 102. Aceto Corp. Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 103. Aceto Corp. Recent Development
Table 104. Mylan Pharmaceuticals Company Details
Table 105. Mylan Pharmaceuticals Business Overview
Table 106. Mylan Pharmaceuticals Product
Table 107. Mylan Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 108. Mylan Pharmaceuticals Recent Development
Table 109. Impax Laboratories Company Details
Table 110. Impax Laboratories Business Overview
Table 111. Impax Laboratories Product
Table 112. Impax Laboratories Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 113. Impax Laboratories Recent Development
Table 114. Pfizer Company Details
Table 115. Pfizer Business Overview
Table 116. Pfizer Product
Table 117. Pfizer Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 118. Pfizer Recent Development
Table 119. Lupin Pharmaceuticals Company Details
Table 120. Lupin Pharmaceuticals Business Overview
Table 121. Lupin Pharmaceuticals Product
Table 122. Lupin Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 123. Lupin Pharmaceuticals Recent Development
Table 124. Glenmark Pharmaceuticals Company Details
Table 125. Glenmark Pharmaceuticals Business Overview
Table 126. Glenmark Pharmaceuticals Product
Table 127. Glenmark Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 128. Glenmark Pharmaceuticals Recent Development
Table 129. Sun Pharmaceutical Company Details
Table 130. Sun Pharmaceutical Business Overview
Table 131. Sun Pharmaceutical Product
Table 132. Sun Pharmaceutical Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 133. Sun Pharmaceutical Recent Development
Table 134. Heritage Pharmaceuticals Company Details
Table 135. Heritage Pharmaceuticals Business Overview
Table 136. Heritage Pharmaceuticals Product
Table 137. Heritage Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 138. Heritage Pharmaceuticals Recent Development
Table 139. Gilead Sciences Company Details
Table 140. Gilead Sciences Business Overview
Table 141. Gilead Sciences Product
Table 142. Gilead Sciences Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 143. Gilead Sciences Recent Development
Table 144. Johnson & Johnson Company Details
Table 145. Johnson & Johnson Business Overview
Table 146. Johnson & Johnson Product
Table 147. Johnson & Johnson Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 148. Johnson & Johnson Recent Development
Table 149. Bristol-Myers Squibb Company Details
Table 150. Bristol-Myers Squibb Business Overview
Table 151. Bristol-Myers Squibb Product
Table 152. Bristol-Myers Squibb Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 153. Bristol-Myers Squibb Recent Development
Table 154. Profounda Company Details
Table 155. Profounda Business Overview
Table 156. Profounda Product
Table 157. Profounda Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 158. Profounda Recent Development
Table 159. Knight Therapeutics Company Details
Table 160. Knight Therapeutics Business Overview
Table 161. Knight Therapeutics Product
Table 162. Knight Therapeutics Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 163. Knight Therapeutics Recent Development
Table 164. Albert David Company Details
Table 165. Albert David Business Overview
Table 166. Albert David Product
Table 167. Albert David Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 168. Albert David Recent Development
Table 169. Wanlong Company Details
Table 170. Wanlong Business Overview
Table 171. Wanlong Product
Table 172. Wanlong Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 173. Wanlong Recent Development
Table 174. Fangsheng Company Details
Table 175. Fangsheng Business Overview
Table 176. Fangsheng Product
Table 177. Fangsheng Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 178. Fangsheng Recent Development
Table 179. KPC Pharmaceuticals Company Details
Table 180. KPC Pharmaceuticals Business Overview
Table 181. KPC Pharmaceuticals Product
Table 182. KPC Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 183. KPC Pharmaceuticals Recent Development
Table 184. Guilin Pharmaceuticals Company Details
Table 185. Guilin Pharmaceuticals Business Overview
Table 186. Guilin Pharmaceuticals Product
Table 187. Guilin Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 188. Guilin Pharmaceuticals Recent Development
Table 189. Pude Pharmaceutica Company Details
Table 190. Pude Pharmaceutica Business Overview
Table 191. Pude Pharmaceutica Product
Table 192. Pude Pharmaceutica Revenue in Antiprotozoal Drugs Business (2015-2020) (US$ Million)
Table 193. Pude Pharmaceutica Recent Development
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antiprotozoal Drugs Market Share by Type: 2020 VS 2026
Figure 2. Amoebic Dysentery Features
Figure 3. Antimalarial Drug Features
Figure 4. Leishmaniasis & Chagas Disease Features
Figure 5. Global Antiprotozoal Drugs Market Share by Application: 2020 VS 2026
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Antiprotozoal Drugs Report Years Considered
Figure 9. Global Antiprotozoal Drugs Market Size (US$ Million), YoY Growth 2015-2026
Figure 10. Global Antiprotozoal Drugs Market Share by Regions: 2020 VS 2026
Figure 11. Global Antiprotozoal Drugs Market Share by Regions (2021-2026)
Figure 12. Global Antiprotozoal Drugs Market Share by Players in 2019
Figure 13. Global Top Antiprotozoal Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antiprotozoal Drugs as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Antiprotozoal Drugs Revenue in 2019
Figure 15. North America Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 16. United States Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 17. Canada Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. Europe Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Germany Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. France Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. U.K. Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Italy Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Russia Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Nordic Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Rest of Europe Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Asia-Pacific Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. China Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Japan Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. South Korea Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Southeast Asia Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. India Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Australia Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Rest of Asia-Pacific Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Latin America Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Mexico Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Brazil Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Middle East & Africa Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Turkey Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Saudi Arabia Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. UAE Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Rest of Middle East & Africa Antiprotozoal Drugs Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Sanofi Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 43. Akthelia Pharmaceuticals Ltd Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 44. GlaxoSmithKline Plc Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 45. Immuron Ltd Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 46. Microbiotix Inc Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 47. Protein Potential LLC Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 48. Dr. Reddy’s Laboratories Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 49. Mission Pharmacal Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 50. Aceto Corp. Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 51. Mylan Pharmaceuticals Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 52. Impax Laboratories Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 53. Pfizer Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 54. Lupin Pharmaceuticals Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 55. Glenmark Pharmaceuticals Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 56. Sun Pharmaceutical Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 57. Heritage Pharmaceuticals Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 58. Gilead Sciences Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 59. Johnson & Johnson Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 61. Profounda Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 62. Knight Therapeutics Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 63. Albert David Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 64. Wanlong Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 65. Fangsheng Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 66. KPC Pharmaceuticals Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 67. Guilin Pharmaceuticals Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 68. Pude Pharmaceutica Revenue Growth Rate in Antiprotozoal Drugs Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…- 重症筋無力症治療薬の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- 末梢動脈疾患（PAD）薬の世界市場（～2026年） Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Drugs Market The global Peripheral Arterial Disease (PAD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Peripheral Arterial Disease (PAD) D…
- シャーガス病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chagas Disease Drug Market The global Chagas Disease Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chagas Disease Drug Scope and Market Size Chagas Disease Drug market is seg…
- メニエール病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Meniere Disease Drugs Market The global Meniere Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Meniere Disease Drugs Scope and Market Size Meniere Disease Drugs marke…